Stock Spotlight: 'Impossible to replicate' LVMH remains a gift for investors

Group shows resilience

James Baxter-Derrington
clock • 3 min read

The world’s biggest luxury conglomerate LVMH continues to deliver for investors despite lockdown woes, with a large debt owed to the moat created by the group’s “virtually impossible to replicate” brand heritage.

This offers the group a strong ability to control pricing, according to Ben Peters, co-portfolio manager of TB Evenlode Global Income, who explained the variety of brands means an investment in LVMH "has the added benefit of diversifying the portfolio even within the consumer goods sector itself". Rory Campbell-Lamerton, co-manager of Esk Global Equity, highlighted the same benefit of the luxury giant: "There is not an aspect of decadence, extravagance and super luxury that LVMH does not have a stake in." Stock Spotlight: Games Workshop still a good play Historic brands also create...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Companies

Monzo fined £21m by FCA for failings in financial crime controls

Monzo fined £21m by FCA for failings in financial crime controls

Around 34,000 high-risk clients onboarded

Linus Uhlig
clock 08 July 2025 • 2 min read
Citi becomes minority investor in HANetf

Citi becomes minority investor in HANetf

Growing interest in European ETFs

Patrick Brusnahan
clock 03 July 2025 • 2 min read
AstraZeneca CEO mulls moving listing to the US – reports

AstraZeneca CEO mulls moving listing to the US – reports

Latest blow to LSE

Linus Uhlig
clock 02 July 2025 • 1 min read
Trustpilot